期刊
CURRENT TOPICS IN MEDICINAL CHEMISTRY
卷 21, 期 2, 页码 126-139出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026620666200922113846
关键词
Hyaluronan (HA); Combination cancer therapy; CD44; Drug delivery; Nano-carriers; Theranostics
资金
- CAMS Innovation Fund for Medical Science [CIFMS 2019-I2M-1-004]
- State Key Laboratory Special Fund [2060204]
- Fundamental Research Funds for the Central Universities [3332019064]
Hyaluronan (HA) is a versatile polymer for constructing drug-loading nanoparticles with targeting ligands, offering a simplified and biocompatible platform for combination cancer therapy. The use of HA-based multidrug nano-carriers presents a highly effective strategy for combating cancers with CD44 overexpression.
Hyaluronan (HA) is a natural linear polysaccharide that has excellent hydrophilicity, biocompatibility, biodegradability, and low immunogenicity, making it one of the most attractive biopolymers used for biomedical researches and applications. Due to the multiple functional sites on HA and its intrinsic affinity for CD44, a receptor highly expressed on various cancer cells, HA has been widely engineered to construct different drug-loading nanoparticles (NPs) for CD44-targeted anti-tumor therapy. When a cocktail of drugs is co-loaded in HA NP, a multifunctional nano-carriers could be obtained, which features as a highly effective and self-targeting strategy to combat cancers with CD44 overexpression. The HA-based multidrug nano-carriers can be a combination of different drugs, various therapeutic modalities, or the integration of therapy and diagnostics (theranostics). Up to now, there arc many types of HA-based multidnig nano-carriers constructed by different formulation strategies, including drug co-conjugates, micelles, nano-gels and hybrid NP of HA and so on. This multidrug nano-carrier takes the full advantages of HA as an NP matrix, drug carriers and targeting ligand, representing a simplified and biocompatible platform to realize the targeted and synergistic combination therapy against the cancers. In this review, recent progress of HA-based multidrug nano-carriers for combination cancer therapy is summarized and the potential challenges for translational applications have been discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据